Clinical Trials Logo

Deafness clinical trials

View clinical trials related to Deafness.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 7

NCT ID: NCT02779192 Not yet recruiting - Clinical trials for Noise Induced Hearing Loss

A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss

PANIHL
Start date: November 2018
Phase: Phase 2
Study type: Interventional

SPI-1005 is a novel oral drug that contains a glutathione peroxidase mimetic (ebselen) that will be tested in subjects with a history of NIHL at risk for additional NIHL. The goal of this multi-center Phase 2b study is to determine whether SPI-1005 is effective in reducing an acute NIHL in this affected population. In this Phase 2b study subjects with prior NIHL will be enrolled and exposed to a calibrated sound challenge (CSC) that induces a slight acute NIHL.

NCT ID: NCT02026479 Not yet recruiting - Clinical trials for Full-frequency Sudden Hearing Loss

Sudden Hearing Loss Multi-center Clinical Trial

Start date: January 2014
Phase: N/A
Study type: Interventional

The incidence of sudden hearing loss is rising obviously resent year, Glucocorticoids have obtained obvious effect in the treatment of sudden deafness. Postauricular hypodermic injection is the latest findings in clinical work and a new noninvasive way of administration which is gradually expanding research. The aim of this experiment is to verify and explore the efficacy and safety of the postauricular injection treatment with different doses of Glucocorticoids.

NCT ID: NCT01967498 Not yet recruiting - Clinical trials for Conductive Hearing Loss

Montelukast for Children With Chronic Otitis Media With Effusion (COME): A Double-blind, Placebo-controlled Study

COME
Start date: November 2013
Phase: N/A
Study type: Interventional

The purpose of our double-blind, placebo controlled study is to test the hypothesis that montelukast therapy might be associated with improved hearing in certain sub populations of children suffering from OME.

NCT ID: NCT01933386 Not yet recruiting - Clinical trials for Single Sided Deafness

Evaluation of Benefit for Treatment of Single Sided Deafness (SSD) Between Two Bone Conduction Prosthetic Devices; Osseointegrated Implant Versus Maxilla Anchored Removable Oral Appliance ("SoundBite")

Start date: September 2013
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to compare the SoundBite™ Hearing System to surgically implanted BCD systems.

NCT ID: NCT01529333 Not yet recruiting - Clinical trials for Mixed Conductive and Sensorineural Hearing Loss, Bilateral

Middle-Ear Implant With MET V Transducer (Aka MET V System)

Start date: May 2012
Phase: N/A
Study type: Interventional

The purpose and objective of this study is to evaluate the safety and efficacy of the MET V System for the treatment of individuals with mixed hearing loss.

NCT ID: NCT01451853 Not yet recruiting - Lung Cancer Clinical Trials

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Start date: January 15, 2018
Phase: Phase 2
Study type: Interventional

Chemotherapy treatment with platinum based agents is well noted to cause ototoxicity. It is the objective of this study to determine the safety and efficacy of SPI-1005 at three dose levels when delivered orally twice daily for 3 days, surrounding each cycle of platinum chemotherapy in head and neck or non-small cell lung cancer patients to prevent and treat chemotherapy induced hearing loss and tinnitus.

NCT ID: NCT00578760 Not yet recruiting - Hearing Loss Clinical Trials

Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity?

Start date: February 2008
Phase: N/A
Study type: Interventional

Aspirin (ASA) has been shown, in an animal model, to attenuate the ototoxic properties of cisplatin. The researchers plan to investigate this in patients undergoing cisplatin chemotherapy. The researchers hypothesise that low-dose aspirin can prevent cisplatin induced ototoxicity in the clinical setting.